Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, presents on the company's lead drug candidate, the potential applications for the drug and the breadth of the market at FNN's Investor Event.
Key points: - Share price up approx 3 per cent year to date.
- Dual-listed company formerly known as Prana Biotechnology.
- Lead drug has orphan drug status for the treatment of Multiple System Atrophy.
- Strong leadership team with proven track record obtaining US FDA approvals.
For more, watch CEO and Chairman, Geoffrey Kempler present
